An observational study in Coronary Stenosis, sponsored by Cordis Corporation. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-07.
Sponsored by Cordis Corporation · Observational
1500 eligible patients will be treated with the commercially available CYPHER® sirolimus-eluting Bx Velocity™ stent. Patients will be followed to twelve months post-procedure, watching for patients that require a repeat procedure on the same diseased area of the coronary artery.
Geographical miss has been associated with treatment failures after intracoronary radiation therapy. This phenomenon, which is secondary to vascular injury outside the treated segment, was strongly correlated with the development of restenosis at the edges of the treated coronary segment. The European and Canadian SIRIUS trials (E and C-SIRIUS) randomized 350 patients with similar baseline characteristics of the US SIRIUS study. Operators used shorter post-dilatation balloons and direct stented 27% of the patients, achieving a 4.0% TLR rate and a 5.1% in-lesion binary restenosis. These somewhat superior results support the concept that refinement in deployment techniques may further improve clinical outcomes of drug-eluting stents.
302 studies on the registry are indexed under Coronary Stenosis; 63 are open to participants now.
This study's enrollment of 1,500 is above the median of 200 across 132 observational studies indexed under Coronary Stenosis.
Browse Coronary Stenosis studies →Cordis Corporation is the lead sponsor of 70 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients needing an intervention and receiving a CYPHER stent.
Exclusion criteria:
No study locations are listed for this record.
This study is completed, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cordis Corporation